Clinical research trials

CLL-002: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia TAILOR. PI: Joseph Stilwill, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MM-002: A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM). PI: Suman Kambhampati, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE-004: OptimICE-PCR: De-Escalation of Therapy in EarlyStage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy. PI: Nisreen Haideri, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE-005: Randomized, Multicentre, Open-Label, Phase III study of Camizestrant + Capivasertib Versus Physician’s Choice of Endocrine-Based Therapy in Patients with Estrogen Receptor-Positive, HER2-Negative Inoperable Locally Advanced or Metastatic Breast Cancer Whose Disease has Progressed on Treatment with Aromatase Inhibitor + CDK4/6 inhibitor. PI: Anis Toumeh, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

WO45654: A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled study evaluating the efficacy and safety of Inavolisib plus a CDK4/6 inhibitor and Letrozole versus placebo plus a CDK4/6 inhibitor and Letrazole in patients with endocrine-sensitive PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer. PI: Anis Toumeh, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

Adjuvant WIDER: A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-toclinical practice patient population with HR+ HER2− early breast cancer. PI: Anis Toumeh, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

V-Intervention (Inclisiran): Phase III. Hyperlipidemia. Evaluation of Inclisiran vs. Placebo for the prevention of major adverse CV and limb events in patients undergoing PCI or PVI for symptomatic CAD/PAD. Principle investigator: Stephen Bloom, MD
Facility: Medical office

COMET-HF (Omecamtiv Mecarbil): Phase III. Reduced Heart Failure HFrEF. Assess efficacy and safety of Omecamtiv Mecarbil in patients with symptomatic HF with severely reduced EF (HFrEF).Principle investigator: Stephen Dickson, MD
Facility: Centerpoint Medical Center

Hermes-HF (Ziltivekimab): Phase III. HFmrEF or HFpEF. Inflammation effects on morbidity and mortality in patients with HFmrEF or HFpEF and systemic inflammation. Principle investigator: Theodore Pope, MD
Facility: Medical office

Prevail DCB: Phase III. Coronary Artery Disease. Prevail DCB in patients with in-stent restenosis (ISR) and a single arm for Prevail DCB on de novo lesions in small vessel disease (DNSV). Principle investigator: Jayasheel Eshcol, MD
Facility: Overland Park Regional Medical Center, Research Medical Center, Centerpoint Medical Center

Lp(a) Frontiers CAVS (Pelacarsen): Phase II. Elevated Lp(a) & Calcified Aortic Stenosis Impact of Lp(a) lowering with pelacarsen on the progression of calcific aortic valve stenosis. Principle investigator: Vasvi Singh, MD
Facility: Medical office

Ocean(a) PRE-EVENT Olpasiran: Phase III. Lp(a) and High Risk CAD Assessing Olpasiran use to prevent first major CV events in participants with elevated Lp(A). Principle investigator: Stephen Bloom, MD
Facility: Medical office

COMPLETE TAVR: Randomized. Aortic Valve Stenosis and CAD: Effectiveness study of complete revasc. With PCI to treat CAD vs. Medical Management Alone in patients with AVS undergoing TAVR. Principle investigator: Jayasheel Eshcol, MD
Facility: Research Medical Center, Centerpoint Medical Center, Overland Park Regional Medical Center, Medical office.

Ocean(a) CCTA (Olpasiran): Phase III. Elevated LP(a) + CAD Evaluating Safety, Tolerability, and Effect of Olpasiran on coronary artery plaque burden assessed by CCTA in patients with stable CAD and elevated Lp(a0. Principle investigator: Stephen Bloom, MD
Facility: Medical office

Amyloid Fat Sample Analysis: High risk for Amyloidosis Histopathological Incidence of Amyloidosis in High Risk Patients Undergoing Cardiac Device Implantation. Principle investigator: Vasvi Singh, MD
Facility: Overland Park Regional Medical Center, Medical office

HLX22-GC-301:A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer. PI: Joseph Stilwill, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

There are currently no research trials.

BELLA: A Phase 2 Study of Relacorilant in Combination with Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA). PI: Shawn Lybarger, DO

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GYN-005: A Phase 1B22 Baseky study of ACR-368 as monotherapy and in combiinatio with Gemcitabien in Adults with platinum-resistant ovarian carcinoma, Endometrial Adenocarcinoma and Urothelial carcinoma based on Acrivon Oncosignature status. PI: K. Shawn Lybarger, DO

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

There are currently no research trials.

DESTINY: For locally advanced or metastatic HER2-expressing Biliary Tract Cancer. Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab. PI: Anis Toumeh, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

Lung04: A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04). PI: Joseph Stilwill, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center